

March 17, 2026

Perseus Proteomics Inc.

President & CEO: Takuya Yokokawa

e-mail: ir@ppmx.com

Perseus Proteomics Inc. Announces Notice of Allowance in the U.S. for Patent Relating to Antibody-Based Radiopharmaceutical Formulation Technology

Perseus Proteomics Inc. hereby announces that its patent application relating to formulation technology for antibody-based radiopharmaceuticals, developed by the Company, has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). This indicates that the USPTO has determined that the application is eligible for patent grant. The patent will be registered upon payment of the prescribed registration fee within the designated period.

Title of Invention: COMPOSITION CONTAINING BUFFER

Application No.: 18/438,751

Patent Applicant: Perseus Proteomics Inc.

The composition containing buffer for which the Notice of Allowance has been received relates to a buffer used in the manufacture of antibody-based radiopharmaceuticals. This invention is significant in that it identifies multiple buffering agents applicable to lyophilized formulations, and the Company believes it may contribute to the broader adoption of radiopharmaceuticals.

The patent has already been granted in Japan, Australia, and Russia, and the application has now received a Notice of Allowance in the United States.

This matter is not expected to have any impact on the Company's financial results forecast for the current fiscal year. However, the Company expects that it will contribute to enhancing corporate value over the medium-to-long term through future business development.

End